NCT05022797View on ClinicalTrials.gov

Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

July 19, 2021

Primary Completion Date

November 22, 2022

Study Completion Date

November 22, 2022

Conditions
Diffuse Large B-Cell LymphomaDrug Toxicity
Interventions
DRUG

Glucarpidase 1000 UNT [Voraxaze]

2 vials of 1000 units per vial

Trial Locations (2)

28033

MD Anderson, Madrid

28034

Hospital Universitario Ramón y Cajal, Madrid

Sponsors

Collaborators (1)

BTG International Inc.
All Listed Sponsors
collaborator

BioClever 2005 S.L.

OTHER

collaborator

Eurofins ADME, S.L.

UNKNOWN

collaborator

NTShub, S.L.

UNKNOWN

collaborator

BTG International Inc.

OTHER

lead

Fundacion CRIS de Investigación para Vencer el Cáncer

OTHER